Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $6.64 Consensus Target Price from Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) has earned an average rating of "Hold" from the twelve brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $6.64.

Several research firms recently issued reports on MRVI. Baird R W downgraded Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Craig Hallum dropped their price target on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a research note on Friday, March 21st. UBS Group decreased their target price on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a report on Friday, March 21st. Finally, Bank of America dropped their target price on Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in MRVI. Bleakley Financial Group LLC increased its holdings in Maravai LifeSciences by 30.1% in the 4th quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company's stock worth $227,000 after acquiring an additional 9,657 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of Maravai LifeSciences during the fourth quarter worth about $155,000. Rhumbline Advisers raised its position in shares of Maravai LifeSciences by 9.9% during the 4th quarter. Rhumbline Advisers now owns 185,221 shares of the company's stock worth $1,009,000 after purchasing an additional 16,712 shares during the last quarter. Y Intercept Hong Kong Ltd raised its position in shares of Maravai LifeSciences by 155.9% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 32,359 shares of the company's stock worth $176,000 after purchasing an additional 19,713 shares during the last quarter. Finally, VELA Investment Management LLC lifted its stake in Maravai LifeSciences by 54.5% in the 4th quarter. VELA Investment Management LLC now owns 148,112 shares of the company's stock valued at $807,000 after buying an additional 52,246 shares in the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Stock Down 5.3%

Shares of NASDAQ:MRVI traded down $0.12 during trading on Tuesday, reaching $2.16. The stock had a trading volume of 1,596,336 shares, compared to its average volume of 2,332,447. The firm's 50-day simple moving average is $2.05 and its 200 day simple moving average is $3.59. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. Maravai LifeSciences has a one year low of $1.67 and a one year high of $10.03. The company has a market capitalization of $550.07 million, a P/E ratio of -1.32 and a beta of 0.25.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The business had revenue of $46.85 million for the quarter, compared to analysts' expectations of $44.01 million. The company's revenue was down 26.9% on a year-over-year basis. As a group, research analysts expect that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.